文献速递脑血管病

利用人工智能降低抗凝治疗患者不依从风险

Using Artificial Intelligence to Reduce the Risk of Nonadherence in Patients on Anticoagulation Therapy.
PubMed 文献 · Stroke · 2017-04-06

一项随机平行组12周研究纳入28例近期缺血性卒中成人患者,评估人工智能平台每日监测对服药依从性的影响。干预组通过AI识别患者、药物和吞咽确认,血浆药物浓度显示依从率100%(15/15),对照组50%(6/12),直接口服抗凝药亚组绝对改善达67%。

要点

  • AI平台每日监测使卒中抗凝患者血浆浓度依从率从50%提升至100%。
  • 直接口服抗凝药患者绝对依从改善达67%。
  • 实时监测可改变服药行为,尤其适用于直接口服抗凝药治疗者。

核心结论

  • 基于人工智能平台的实时监测可提高卒中抗凝治疗患者的服药依从性,尤其对直接口服抗凝药患者效果更明显。

研究设计与样本

  • 随机平行组12周研究,纳入28例近期诊断缺血性卒中且接受任何抗凝治疗的成人,随机分为AI平台每日监测组和不监测对照组。

主要发现

  • 全部患者平均(SD)年龄57岁(13.2岁),女性占53.6%。
  • 基于AI平台的累计依从率平均(SD)为90.5%(7.5%)。
  • 血浆药物浓度显示干预组依从率100%(15/15),对照组50%(6/12)。
  • 直接口服抗凝药患者绝对依从改善增至67%。

关键数值与推荐

  • 干预组血浆药物浓度依从率100%(15/15),对照组50%(6/12)。
  • 直接口服抗凝药患者绝对改善为67%。
  • AI平台累计依从率平均(SD)90.5%(7.5%)。

临床怎么用

  • 对服用直接口服抗凝药的卒中患者,可考虑采用AI实时监测辅助提高依从性。
  • 常规实验室检查不能可靠反映依从性,实时监测有助于发现不依从。

局限性

  • 样本量较小(n=28),研究周期仅12周,结论需更大样本和更长随访验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: This study evaluated the use of an artificial intelligence platform on mobile devices in measuring and increasing medication adherence in stroke patients on anticoagulation therapy. The introduction of direct oral anticoagulants, while reducing the need for monitoring, have also placed pressure on patients to self-manage. Suboptimal adherence goes undetected as routine laboratory tests are not reliable indicators of adherence, placing patients at increased risk of stroke and bleeding. METHODS: A randomized, parallel-group, 12-week study was conducted in adults (n=28) with recently diagnosed ischemic stroke receiving any anticoagulation. Patients were randomized to daily monitoring by the artificial intelligence platform (intervention) or to no daily monitoring (control). The artificial intelligence application visually identified the patient, the medication, and the confirmed ingestion. Adherence was measured by pill counts and plasma sampling in both groups. RESULTS: For all patients (n=28), mean (SD) age was 57 years (13.2 years) and 53.6% were women. Mean (SD) cumulative adherence based on the artificial intelligence platform was 90.5% (7.5%). Plasma drug concentration levels indicated that adherence was 100% (15 of 15) and 50% (6 of 12) in the intervention and control groups, respectively. CONCLUSIONS: Patients, some with little experience using a smartphone, successfully used the technology and demonstrated a 50% improvement in adherence based on plasma drug concentration levels. For patients receiving direct oral anticoagulants, absolute improvement increased to 67%. Real-time monitoring has the potential to increase adherence and change behavior, particularly in patients on direct oral anticoagulant therapy. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02599259.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Labovitz DL, Shafner L, Reyes Gil M, et al. Using Artificial Intelligence to Reduce the Risk of Nonadherence in Patients on Anticoagulation Therapy. Stroke. 2017. PMID: 28386037. doi:10.1161/STROKEAHA.116.016281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。